TDMS No. 20006 - 01 Test Type: 90-DAY Route: GAVAGE Species/Strain: RATS/F 344	P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a) INDOLE-3-CARBINOL CAS Number: 700-06-1	Date Report Reqsted: 06/04/2007 Time Report Reqsted: 16:29:44 First Dose M/F: 08/31/04 / 08/30/04 Lab: SRI
	F1_R2	
C Number:	C20006	
Lock Date:	03/07/2006	
Cage Range:	ALL	
Date Range:	ALL	
Reasons For Removal:	ALL	
Removal Date Range:	ALL	

- Treatment Groups: Include ALL
- **TDMSE Version:**1.7.0

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

INDOLE-3-CARBINOL

CAS Number: 700-06-1

Date Report Reqsted: 06/04/2007 Time Report Reqsted: 16:29:44 First Dose M/F: 08/31/04 / 08/30/04 Lab: SRI

FISCHER 344 RATS MALE	0 MG/KG	18.75 MG/KG	37.5 MG/KG	75 MG/KG	150 MG/KG
Disposition Summary					
Animals Initially in Study Early Deaths	10	10	10	10	10
Survivors Terminal Sacrifice Animals Examined Microscopically	10 10	10 10	10 10	10 10	10 10
ALIMENTARY SYSTEM					
Esophagus	(10)	(0)	(0)	(0)	(0)
Inflammation, Chronic Intestine Small, Duodenum Lamina Propria, Lipidosis Lymphatic, Ectasia	(10)	(10)	(10)	(10) 1 (10%) 1 (10%)	(10) 10 (100%) 10 (100%)
Intestine Small, Jejunum Lamina Propria, Lipidosis Lymphatic, Ectasia	(10)	(9) 1 (11%) 1 (11%)	(10) 1 (10%) 1 (10%)	(10) 5 (50%) 5 (50%)	(100%) (10) 10 (100%) 10 (100%)
Liver	(10)	(10)	(10%)	(10)	(10)
Hemorrhage Hepatodiaphragmatic Nodule Infiltration Cellular, Mixed Cell	2 (20%)		1 (10%)	1 (10%) 1 (10%)	
Capsule, Fibrosis Hepatocyte, Necrosis				1 (10%) 1 (10%)	1 (10%)
Hepatocyte, Vacuolization Cytoplasmic Mesentery	4 (40%) (2)	4 (40%) (0)	2 (20%) (0)	4 (40%) (0)	2 (20%) (0)
Accessory Spleen Fat, Necrosis	1 (50%) 1 (50%)		(0)		(0)
CARDIOVASCULAR SYSTEM					
Heart	(10)	(0)	(0)	(0)	(0)
Cardiomyopathy Infiltration Cellular, Mixed Cell	1 (10%) 3 (30%)				
ENDOCRINE SYSTEM					
Adrenal Cortex	(10)	(0)	(0)	(0)	(0)

TDMS No. 20006 - 01 Test Type: 90-DAY Route: GAVAGE Species/Strain: RATS/F 344	P03: INCIDENCE RATE	S OF NON-NEOPLASTIC LE INDOLE-3-CARBINOL CAS Number: 700-06-) Date Report Reqsted: 06/04/200 Time Report Reqsted: 16:29:44 First Dose M/F: 08/31/04 / 08/30/ Lab: SRI		
FISCHER 344 RATS MALE	0 MG/KG	18.75 MG/KG	37.5 MG/KG	75 MG/KG	150 MG/KG	
Accessory Adrenal Cortical Nodule	2 (20%)					
GENERAL BODY SYSTEM						
None						
GENITAL SYSTEM						
None						
HEMATOPOIETIC SYSTEM						
Lymph Node, Mesenteric Hemorrhage Lipidosis	(7) 1 (14%)	(10) 2 (20%)	(9) 1 (11%)	(10)	(10) 5 (50%)	
Lymphatic, Ectasia Spleen Pigmentation	(10) 3 (30%)	2 (20%) (0)	1 (11%) (0)	(0)	5 (50%) (0)	
INTEGUMENTARY SYSTEM						
None						
MUSCULOSKELETAL SYSTEM						
None						
NERVOUS SYSTEM						
None						
RESPIRATORY SYSTEM						
Lung Hemorrhage Inflammation, Chronic Alveolar Epithelium, Hyperplasia	(10) 3 (30%) 1 (10%)	(0)	(0)	(0)	(0)	

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a) Date Report Regsted: 06/04/2007 TDMS No. 20006 - 01 Test Type: 90-DAY **INDOLE-3-CARBINOL** Time Report Reqsted: 16:29:44 Route: GAVAGE CAS Number: 700-06-1 First Dose M/F: 08/31/04 / 08/30/04 Species/Strain: RATS/F 344 Lab: SRI **FISCHER 344 RATS MALE** 0 MG/KG 18.75 MG/KG 37.5 MG/KG 75 MG/KG 150 MG/KG (0) (10) (0) (0) (0) Nose Nasolacrimal Duct, Inflammation, Chronic 1 (10%) SPECIAL SENSES SYSTEM Harderian Gland (10) (0) (0) (0) (0) Inflammation, Chronic URINARY SYSTEM Kidney (10) (0) (0) (0) (0) Nephropathy

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

INDOLE-3-CARBINOL

CAS Number: 700-06-1

Date Report Reqsted: 06/04/2007 Time Report Reqsted: 16:29:44 First Dose M/F: 08/31/04 / 08/30/04 Lab: SRI

FISCHER 344 RATS MALE	300 MG/KG		
Disposition Summary			
Animals Initially in Study Early Deaths	10		
Survivors Terminal Sacrifice Animals Examined Microscopically	10 10		
ALIMENTARY SYSTEM			
Esophagus Inflammation, Chronic Intestine Small, Duodenum Lamina Propria, Lipidosis Lymphatic, Ectasia Intestine Small, Jejunum Lamina Propria, Lipidosis Lymphatic, Ectasia Liver Hemorrhage Hepatodiaphragmatic Nodule Infiltration Cellular, Mixed Cell Capsule, Fibrosis Hepatocyte, Necrosis Hepatocyte, Vacuolization Cytoplasmic Mesentery Accessory Spleen Fat, Necrosis	(9) 1 (11%) (10) 10 (100%) 10 (100%) 10 (100%) 10 (100%) (10) 1 (10%) 2 (20%) (0)		
CARDIOVASCULAR SYSTEM		 	
Heart Cardiomyopathy Infiltration Cellular, Mixed Cell	(10) 3 (30%) 3 (30%)		
ENDOCRINE SYSTEM			
Adrenal Cortex	(10)		

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

INDOLE-3-CARBINOL

CAS Number: 700-06-1

Date Report Reqsted: 06/04/2007 Time Report Reqsted: 16:29:44 First Dose M/F: 08/31/04 / 08/30/04 Lab: SRI

FISCHER 344 RATS MALE	300 MG/KG
	4 (400())
Accessory Adrenal Cortical Nodule	1 (10%)
GENERAL BODY SYSTEM	
None	
GENITAL SYSTEM	
None	
HEMATOPOIETIC SYSTEM	
Lymph Node, Mesenteric	(10)
Hemorrhage Lipidosis	1 (10%) 10 (100%)
Lymphatic, Ectasia Spleen	10 (100%) (10)
Pigmentation	1 (10%)
INTEGUMENTARY SYSTEM	
None	
MUSCULOSKELETAL SYSTEM	
None	
NERVOUS SYSTEM	
None	
RESPIRATORY SYSTEM	
Lung	(10)
Hemorrhage Inflammation, Chronic	1 (10%)
Alveolar Epithelium, Hyperplasia	

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

INDOLE-3-CARBINOL

CAS Number: 700-06-1

Date Report Reqsted: 06/04/2007 Time Report Reqsted: 16:29:44 First Dose M/F: 08/31/04 / 08/30/04 Lab: SRI

FISCHER 344 RATS MALE	300 MG/KG	
Nose Nasolacrimal Duct, Inflammation, Chronic	(10)	
SPECIAL SENSES SYSTEM		
Harderian Gland Inflammation, Chronic	(10) 1 (10%)	
URINARY SYSTEM		
Kidney Nephropathy	(10) 2 (20%)	

*** END OF MALE ***

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

INDOLE-3-CARBINOL

CAS Number: 700-06-1

Date Report Reqsted: 06/04/2007 Time Report Reqsted: 16:29:44 First Dose M/F: 08/31/04 / 08/30/04 Lab: SRI

FISCHER 344 RATS FEMALE	0 MG/KG	18.75 MG/KG	37.5 MG/KG	75 MG/KG	150 MG/KG
Disposition Summary					
Animals Initially in Study Early Deaths Survivors	10	10	10	10	10
Terminal Sacrifice Animals Examined Microscopically	10 10	10 10	10 10	10 10	10 10
ALIMENTARY SYSTEM					
Intestine Small, Duodenum Lamina Propria, Lipidosis Lymphatic, Ectasia	(10)	(10)	(10)	(10)	(10) 9 (90%) 9 (90%)
Intestine Small, Jejunum Lamina Propria, Lipidosis Lymphatic, Ectasia	(10)	(10)	(10) 1 (10%) 1 (10%)	(10) 10 (100%) 10 (100%)	(10) 10 (100%) 10 (100%)
Liver Eosinophilic Focus Hemorrhage	(10) 1 (10%)	(10)	(10)	(10) (10%)	(10)
Hepatodiaphragmatic Nodule Infiltration Cellular, Mixed Cell Mesentery	2 (20%) (0)	1 (10%)	2 (20%) (1)	1 (10%)	2 (20%) 2 (20%) (1)
Fat, Necrosis Pancreas	(0)	(0) (0)	(1) 1 (100%) (0)	(0) (0)	(1) 1 (100%) (0)
Atrophy CARDIOVASCULAR SYSTEM					
Heart Cardiomyopathy	(10) 2 (20%)	(0)	(0)	(0)	(0)
ENDOCRINE SYSTEM					
Adrenal Cortex Accessory Adrenal Cortical Nodule	(10) 2 (20%)	(0)	(0)	(0)	(0)
Pituitary Gland Rathke's Cleft, Hemorrhage	(10)	(0)	(1) 1 (100%)	(0)	(0)

TDMS No. 20006 - 01 Test Type: 90-DAY Route: GAVAGE Species/Strain: RATS/F 344	P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a) INDOLE-3-CARBINOL CAS Number: 700-06-1			(a) Date Report Reqsted: 06/04/20 Time Report Reqsted: 16:29:44 First Dose M/F: 08/31/04 / 08/3 Lab: SRI		
FISCHER 344 RATS FEMALE	0 MG/KG	18.75 MG/KG	37.5 MG/KG	75 MG/KG	150 MG/KG	
GENERAL BODY SYSTEM						
None						
GENITAL SYSTEM						
Ovary Cyst	(10)	(0)	(0)	(0)	(0)	
HEMATOPOIETIC SYSTEM						
Lymph Node Mediastinal, Hemorrhage Mediastinal, Hyperplasia, Lymphoid	(0)	(0)	(1) 1 (100%) 1 (100%)	(0)	(0)	
Lymph Node, Mesenteric Lipidosis	(10)	(10)	(10)	(10)	(10) 3 (30%) 3 (20%)	
Lymphatic, Ectasia Spleen Pigmentation	(10) 2 (20%)	(0)	(0)	(0)	3 (30%) (0)	
INTEGUMENTARY SYSTEM						
Skin Cyst Epithelial Inclusion	(10)	(0)	(0)	(0)	(0)	
MUSCULOSKELETAL SYSTEM						
None						
NERVOUS SYSTEM						
None						
RESPIRATORY SYSTEM						
Lung	(10)	(0)	(0)	(0)	(0)	

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

INDOLE-3-CARBINOL

CAS Number: 700-06-1

Date Report Reqsted: 06/04/2007 Time Report Reqsted: 16:29:44 First Dose M/F: 08/31/04 / 08/30/04 Lab: SRI

FISCHER 344 RATS FEMALE	0 MG/KG	18.75 MG/KG	37.5 MG/KG	75 MG/KG	150 MG/KG
Hemorrhage Nose Inflammation, Chronic	1 (10%) (10) 1 (10%)	(0)	(0)	(0)	(0)
SPECIAL SENSES SYSTEM					
Harderian Gland Inflammation, Suppurative	(10)	(0)	(0)	(0)	(0)
URINARY SYSTEM					
Kidney Nephropathy	(10)	(0)	(0)	(0)	(0)

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

INDOLE-3-CARBINOL

CAS Number: 700-06-1

Date Report Reqsted: 06/04/2007 Time Report Reqsted: 16:29:44 First Dose M/F: 08/31/04 / 08/30/04 Lab: SRI

FISCHER 344 RATS FEMALE	300 MG/KG	
Disposition Summary		
Animals Initially in Study Early Deaths Survivors	10	
Terminal Sacrifice Animals Examined Microscopically	10 10	
ALIMENTARY SYSTEM		
Intestine Small, Duodenum Lamina Propria, Lipidosis Lymphatic, Ectasia Intestine Small, Jejunum Lamina Propria, Lipidosis Lymphatic, Ectasia Liver Eosinophilic Focus Hemorrhage Hepatodiaphragmatic Nodule Infiltration Cellular, Mixed Cell Mesentery	(10) 10 (100%) 10 (100%) (10) 10 (100%) 10 (100%) (10)	
Fat, Necrosis Pancreas Atrophy	1 (100%) (10) 2 (20%)	
CARDIOVASCULAR SYSTEM		
Heart Cardiomyopathy	(10)	
ENDOCRINE SYSTEM		
Adrenal Cortex Accessory Adrenal Cortical Nodule Pituitary Gland Rathke's Cleft, Hemorrhage	(10) 1 (10%) (10)	

TDMS No. 20006 - 01 Test Type: 90-DAY Route: GAVAGE Species/Strain: RATS/F 344	P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a) INDOLE-3-CARBINOL CAS Number: 700-06-1	Date Report Reqsted: 06/04/2007 Time Report Reqsted: 16:29:44 First Dose M/F: 08/31/04 / 08/30/04 Lab: SRI
FISCHER 344 RATS FEMALE	300 MG/KG	
GENERAL BODY SYSTEM		
None		
GENITAL SYSTEM		
Ovary Cyst	(10) 1 (10%)	
HEMATOPOIETIC SYSTEM		
Lymph Node Mediastinal, Hemorrhage Mediastinal, Hyperplasia, Lymphoid Lymph Node, Mesenteric Lipidosis Lymphatic, Ectasia Spleen Pigmentation	(0) (10) 9 (90%) 9 (90%) (10) 4 (40%)	
INTEGUMENTARY SYSTEM		
Skin Cyst Epithelial Inclusion	(10) 1 (10%)	
MUSCULOSKELETAL SYSTEM None		
NERVOUS SYSTEM None		
RESPIRATORY SYSTEM		
Lung	(10)	

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a) INDOLE-3-CARBINOL

CAS Number: 700-06-1

Date Report Reqsted: 06/04/2007 Time Report Reqsted: 16:29:44 First Dose M/F: 08/31/04 / 08/30/04 Lab: SRI

FISCHER 344 RATS FEMALE	300 MG/KG	
Hemorrhage	1 (10%)	
Nose Inflammation, Chronic	(10) 1 (10%)	
SPECIAL SENSES SYSTEM		
Harderian Gland Inflammation, Suppurative	(10) 1 (10%)	
URINARY SYSTEM		
Kidney Nephropathy	(10) 2 (20%)	

*** END OF REPORT ***